Pediatric Endocrinology Diabetes and Metabolism

Full text

3/2026 vol. 32
Case report

Refractory hypoparathyroidism in paediatric autoimmune polyglandular syndrome type 1: successful long-term use of teriparatide

Carolina Perez 1
,
Nicolas Adame 1
,
Catalina Hernandez 2
,
Maria Paula Sarmiento 3

  1. Department of Paediatrics, Universidad Industrial de Santander, Bucaramanga, Colombia

  2. Department of Medicine, Universidad Pedagógica y Tecnológica de Colombia, Tunja, Colombia

  3. Department of Paediatric Endocrinology, Fundación Oftalmológica de Santander, Bucaramanga, Colombia

Pediatr Endocrinol Diabetes Metab 2026; 32 (3): 223-229

DOI: https://doi.org/10.5114/pedm.2026.163483
Data publikacji online: 2026/09/14
Article file
0431_Refractory hypoparathyroidism.pdf
Confronting perimenopausal women’s knowledge of coronary heart disease with their health behaviours. Controversial role of hormone replacement therapy in the protection of coronary heart disease
  1. Navarrete-Tapia U. Síndrome poliglandular autoinmune. Rev Med Hosp Gen Mex 2013; 76: 143–152.
  2. Bello MO, Garla VV. Polyglandular autoimmune syndrome type I. Treasure Island (FL): StatPearls Publishing; 2023. Available at: https://www.ncbi.nlm.nih.gov/books/NBK537211/ (accessed 3 Feb 2025).
  3. Husebye ES, Anderson MS, Kämpe O. Autoimmune polyendocrine syndromes. N Engl J Med 2018; 378: 1132–1141. doi: 10.1056/NEJMra1713301.
  4. Cusano NE, Rubin MR, McMahon DJ, et al. Therapy of hypoparathyroidism with PTH(1–84): a prospective four-year investigation of efficacy and safety. J Clin Endocrinol Metab 2013; 98: 137–144. doi: 10.1210/jc.2012-2984.
  5. ‌Winer KK, Fulton KA, Albert PS, Cutler GB Jr. Effects of pump versus twice-daily injection delivery of synthetic parathyroid hormone 1-34 in children with severe congenital hypoparathyroidism. J Pediatr 2014; 165: 556–563.e1. doi: 10.1016/j.jpeds.2014.04.060.
  6. ‌Winer KK, Kelly A, Johns A, et al. Long-term parathyroid hormone 1-34 replacement therapy in children with hypoparathyroidism. J Pediatr 2018; 203: 391–399.e1. doi: 10.1016/j.jpeds.2018.08.010.
  7. ‌Winer KK, Sinaii N, Peterson D, et al. Effects of once versus twice-daily parathyroid hormone 1–34 therapy in children with hypoparathyroidism. J Clin Endocrinol Metab 2008; 93: 3389–3395. doi: 10.1210/jc.2007-2552.
  8. Ferre EMN, Rose SR, Rosenzweig SD, et al. Redefining the clinical presentation of autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy. JCI Insight 2016; 1: e88782. doi: 10.1172/jci.insight.88782.
  9. Alimohammadi M, Björklund P, Hallgren A, et al. Autoimmune polyendocrine syndrome type 1 and NALP5, a parathyroid autoantigen. N Engl J Med 2008; 358: 1018–1028. doi: 10.1056/NEJMoa0706487.
  10. Halabi I, Barohom M, Peleg S, et al. Case report: severe hypocalcemic episodes due to autoimmune enteropathy. Front Endocrinol (Lausanne) 2021; 12: 645279. doi: 10.3389/fendo.2021.645279
  11. Rueda Perea MA, Coronado Silva CI, Fernández Franco JA, et al. Fisiopatología del gen AIRE en la endocrinopatía múltiple autoinmune: una revisión de la literatura. Rev Colomb Endocrinol Diabet Metab 2024; 11: e877. doi: 10.53853/encr.11.4.877..
  12. Oftedal BE, Wolff ASB, Bratland E, et al. Radioimmunoassay for autoantibodies against interferon omega; its use in the diagnosis of autoimmune polyendocrine syndrome type I. Clin Immunol 2008; 129: 163–169. doi: 10.1016/j.clim.2008.07.002.
  13. Kisand K, Peterson P. Autoimmune polyendocrinopathy candidiasis ectodermal dystrophy. J Clin Immunol 2015; 35: 463–478. doi: 10.1007/s10875-015-0176-y.
  14. Betterle C, Greggio NA, Volpato M. Clinical review 93: autoimmune polyglandular syndrome type 1. J Clin Endocrinol Metab 1998; 83: 1049–1055. doi: 10.1210/jcem.83.4.4682.
  15. Wang YB, Zhou W, Liang L, et al. Characterization of the clinical and genetic spectrum of autoimmune polyendocrine syndrome type 1 in Chinese case series. Orphanet J Rare Dis 2021; 16: 296. doi: 10.1186/s13023-021-01933-y.
  16. Bruserud Ø, Oftedal BE, Landegren N, et al. A longitudinal follow-up of autoimmune polyendocrine syndrome type 1. J Clin Endocrinol Metab 2016; 101: 2975–2983. doi: 10.1210/jc.2016-1821.
  17. Vahle JL, Sato M, Long GG, et al. Skeletal changes in rats given daily subcutaneous injections of teriparatide for 2 years and relevance to human safety. Toxicol Pathol 2002; 30: 312–321. doi: 10.1080/01926230252929882.
  18. Sencar M, Calapkulu M, Unsal I, et al. Synthetic human parathyroid hormone 1–34 vs calcitriol and calcium in the treatment of hypoparathyroidism. Endocrine Abstracts 2020; 70: EP548. doi: 10.1530/endoabs.70.EP548.
  19. Winer KK, Yanovski JA, Cutler GB Jr. Synthetic human parathyroid hormone 1-34 vs calcitriol and calcium in the treatment of hypoparathyroidism. JAMA 1996; 276: 631–636.
  20. Bernardor J, Flammier S, Cabet S, et al. Intermittent bi‑daily subcutaneous teriparatide administration in children with hypoparathyroidism: a single‑center experience. Front Pediatr 2021; 9: 764040. doi: 10.3389/fped.2021.764040.
  21. Theman TA, Collins MT, Dempster DW, et al. PTH(1–34) replacement therapy in a child with hypoparathyroidism caused by a sporadic calcium receptor mutation. J Bone Miner Res 2009; 24: 964–973. doi: 10.1359/jbmr.081233.
  22. Linglart A, Rothenbuhler A, Gueorguieva I, et al. Long-term results of continuous subcutaneous recombinant PTH (1-34) infusion in children with refractory hypoparathyroidism. J Clin Endocrinol Metab 2011; 96: 3308–3312. doi: 10.1210/jc.2011-1359.
  23. Shiohara M, Shiozawa R, Kurata K, et al. Effect of parathyroid hormone administration in a patient with severe hypoparathyroidism caused by gain-of-function mutation of calcium-sensing receptor. Endocr J 2006; 53: 797–802. doi: 10.1507/endocrj.k06-053.
  24. Winer K, Sinaii N, Reynolds J, et al. Long-term treatment of 12 children with chronic hypoparathyroidism: a randomized trial comparing synthetic human parathyroid hormone 1–34 versus calcitriol and calcium. J Clin Endocrinol Metab 2010; 95: 2680–2688. doi: 10.1210/jc.2009-2464.
  25. Bhatt N, Heh J, Hudspeth, et al. Teriparatide therapy in a 4-month-old with severe hypoparathyroidism. J Pediatr Pharmacol Ther 2022; 27: 80–84. doi: 10.5863/1551-6776-27.1.80.
  26. Dayal D, Gupta A, Gupta S, et al. Recombinant parathyroid hormone for hypoparathyroidism in children: a narrative review. Pediatr Endocrinol Diabetes Metab 2019; 25: 194–201. doi: 10.5114/pedm.2019.89642.
  27. Bali R, Al-Khalifah R. Recombinant PTH infusion in a child with Sanjad-Sakati syndrome refractory to conventional therapy. JCEM Case Rep 2024; 2: luae059. doi: 10.1210/jcemcr/luae059.
  28. Fox A, Gilbert R. Use of teriparatide in a four year old patient with autosomal dominant hypocalcaemia. Arch Dis Child 2016; 101: e2. doi: 10.1136/archdischild-2016-311535.66.
  29. Hendy G, Canaff L. Calcium-sensing receptor, proinflammatory cytokines and calcium homeostasis. Semin Cell Dev Biol 2016; 49: 37–43. doi: 10.1016/j.semcdb.2015.11.006.
  30. Chinoy A, Skae M, Babiker A, et al. Impact of intercurrent illness on calcium homeostasis in children with hypoparathyroidism: a case series. Endocr Connect 2017; 6: 589–594. doi: 10.1530/EC-17-0234.
  31. Cardona E, Builes-Barrera CA, Román-González A. Treatment of hypoparathyroidism with parathyroid hormone. Rev Colomb Endocrinol Diabetes Metab 2019; 6: 35–41. doi: 10.53853/encr.6.1.466.
  32. Bandeira L, Lewiecki EM. Anabolic therapy for osteoporosis: update on efficacy and safety. Arch Endocrinol Metab 2022; 66: 707-716. doi: 10.20945/2359-3997000000566.
  33. U.S. Food and Drug Administration. Center for Drug Evaluation and Research. Approval Letter for NDA 021318/S-054, Forteo (teriparatide injection). 2020. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/021318Orig1s054.pdf (accessed 3 Feb 2025).
  34. Vahle JL, Long GG, Sandusky G, et al. Bone neoplasms in F344 rats given teriparatide [rhPTH(1–34)] are dependent on duration of treatment and dose. Toxicol Pathol 2004; 32: 426–438. doi: 10.1080/01926230490462138.
  35. Abdulelah A, Haddad B, Alhajahjeh A. The risk of developing osteosarcoma after teriparatide use: a systematic review. Orthop Res Rev 2023; 15: 191–198. doi: 10.2147/ORR.S408718.
  36. Dulcey SLA, Theran JS, Caltagirone R. Síndrome poliglandular auto-inmune: revisión de una condición clínica subestimada. Rev Av Salud 2023; 6: 55–69. doi: 10.21897/25394622.3222.
SUBMIT YOUR PAPER
Share
without publication fees
Integrated with
integrated with publons
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications